108 results about "Tumor Stem Cells" patented technology

The invention discloses a tumor stem cell targeting virus-like drug carrier as well as a preparation method and application thereof. The drug carrier provided by the invention can improve the cell uptake efficiency by simulating the physical surface characteristics of a biological system, and can directly target tumor stem cells. Besides, the drug carrier has targeting property, so that healthy tissues can be protected, the side effects of the loaded drug such as PTC209 in high-dose independent use are obviously reduced, the reaction to tumor stem cells is effectively enhanced, tumor proliferation and metastasis are inhibited, and the drug resistance of drug combination such as cis-platinum is reduced.

The invention belongs to the field of deep learning and medical image analysis, provides a glioma stem cell image segmentation method and system, and aims to solve the problems that glioma stem cells are high in morphological heterogeneity, fuzzy in boundary and prone to missing detection of tiny targets. On the basis of a deep learning network model framework, three-stage improvement is carried out: in a preprocessing stage, a dynamic data enhancement strategy is introduced, and image enhancement is carried out on a pathological image through combination of CLAHE and a Gaussian filtering algorithm; in the feature extraction stage, a bidirectional feature pyramid network (BiFPN) and a BiFPN module are adopted to realize efficient fusion of cross-scale features, and more accurate cell image segmentation and cell counting are realized.

The invention belongs to the technical field of genetic engineering and biological medicine, and particularly discloses a tumor stem cell targeting plasmid based on a logic gating circuit, a nano-carrier and a preparation method and application of the tumor stem cell targeting plasmid and the nano-carrier. The tumor stem cell targeting plasmid provided by the invention comprises a first plasmid pGal4 and a second plasmid pUAS, a logic AND gate circuit based on protein degradation is designed by utilizing two transcription factors Sox4 and Maff specifically expressed by liver cancer stem cells, and only the liver cancer stem cells with Sox4 and Maff simultaneously highly expressed can express stable target protein GAL4; meanwhile, a target protein GAL4 of an AND gate circuit is set as a primary signal by utilizing a cascade amplification principle of signal transduction, and the signal is used for driving expression (secondary signal) of downstream GSDMD-N and immune activation factors and improving the expression quantity of GSDMD-N in liver cancer stem cells, so that specific pyroptosis of tumor stem cells is induced, and the effect of cancer immunotherapy is enhanced.

A system and method for preparing a cancer vaccine (and optionally purifying the blood) has a blood filtration system, controlled by a processing unit, for filtering exogenous blood plasma to isolate tumor cells, tumor stem cells and tumor breakdown products. The blood filtration system filter may include multiple layers having differently sized apertures to retain differently sized materials (from among tumor cells of different sizes, tumor stem cells and tumor breakdown products. A device directs electromagnetic radiation at the separated tumor cells, tumor stem cells and / or tumor breakdown products. The electromagnetic radiation may cause the separated tumor cells, separated tumor stem cells and / or separated tumor breakdown products (for example tumor protein such as DNA and / or tumor exosomes) to have a coagulated outer layer such as by degrading the outer surface. The electromagnetic radiation may have a UV wavelength. A conical coil improves flow rate uniformity. Tumor exosomes may be centrifuged.

The invention provides an application of a human C1orf186 gene or a human C1orf186 protein in preparation of a targeted therapeutic drug for ovarian cancer, and relates to the technical field of biomedical engineering. The invention relates to an application of a human C1orf186 gene or a human C1orf186 protein in preparation of an ovarian cancer targeted therapy drug. Experiments prove that C1orf186 is an ovarian cancer cell surface specific membrane protein molecule, a C1orf186 positive cell population has tumor stem cell characteristics, and prepared human C1orf186 lentivirus packaging plasmids and other targeted therapeutic drugs have an obvious inhibition effect on the growth of ovarian cancer. Therefore, the invention provides a specific target C1orf186 for molecular therapy of the ovarian cancer, also provides several targeted drug types, and more importantly provides a thought for treating the ovarian cancer by using the anti-C1orf186 targeted drug, thereby laying a foundation for deeply researching the function of the C1orf186. Meanwhile, the invention provides reliable theoretical basis and experimental data for clinical treatment of ovarian cancer, and has important significance and wide prospects.

The invention discloses a preparation method of 6-phenyl-2, 3, 4, 5- The invention discloses a 2, 2 '-bipyridine platinum (II)-guanine N-heterocyclic carbene complex and a preparation method and application thereof, and particularly relates to the complex shown in the specification, the complex has dual inhibitory activity on tumor cells and tumor stem cells at the same time, the problem of platinum drug resistance caused by the tumor stem cells, glutathione and other proteins can be solved, and the drug resistance of the tumor cells and the glutathione can be improved. The compound can be used for preparing drugs for treating various malignant tumors, especially drugs for treating malignant tumors resistant to existing chemotherapeutic drugs. The preparation method is simple and easy to operate. In addition, the 6-phenyl-2, 2 '-bipyridine ligand disclosed by the invention contains carbon anions with relatively strong electron donating ability, and compared with a terpyridine ligand, the 6-phenyl-2, 2'-bipyridine ligand disclosed by the invention can further stabilize a metal ion center, so that the ability of resisting GSH interference is improved, and better stability is shown.

The application belongs to the field of pharmacy, and particularly relates to a whole-process targeting polypeptide molecule with the functions of targeting brain capillary endothelial cells, tumor neovascular endothelial cells, tumor pseudo vascular, tumor cells and tumor stem cells, a stable and optimized polypeptide molecule, and a modified complex and drug delivery system for tumor diagnosis and treatment. The application prepares a whole-process targeting polypeptide WVAP and a WVAP modified drug and high polymer carrier material, and applies the WVAP to the construction of a drug delivery system for tumor imaging and targeted therapy. The results show that the WVAP can cross the blood-brain barrier, target tumor neovascular and cross the blood-tumor barrier, target tumor pseudo vascular, tumor cells and tumor stem cells; and the nano drug delivery system constructed by the WVAP modified high polymer carrier material can effectively deliver the loaded drug to the brain, target tumor tissues, and significantly improve the anti-tumor efficacy.

An in vivo and in vitro editing preparation method for CAR-MΦ targeting tumor stem cells, and a use thereof. The invention provides a chimeric antigen receptor-macrophage (CAR-MΦ) and a nano-carrier based on self-assembled nano-micelles, which can be applied to immunotherapy of glioma. According to the present invention, (PA)2 peptide nano-micelles loaded with CD133-CAR plasmids are constructed, and a citraconic anhydride-modified dextran, which is a group targeting macrophage specific target CD206, is adopted for modification. The carrier is used to realize CAR editing of macrophage in vivo and in vitro, so as to facilitate the re-education of tumor-related macrophage from an M2 phenotype to an M1 phenotype. At the same time, the surface markers of tumor stem cells are targeted to accurately target the tumor stem cells, phagocytize tumor cells, activate tumor immunity, remodel the tumor inhibition microenvironment and specifically kill brain glioma stem cells, thereby efficiently treating brain glioma.

The invention belongs to the technical field of anti-tumor drugs, and particularly relates to a flexible drug-loaded cell microparticle capable of efficiently targeting tumors and a preparation method of the flexible drug-loaded cell microparticle. Comprising tumor cell-derived drug-loaded microparticles coated with chemotherapeutic drugs, and a flexible regulator modified on the surfaces of the tumor cell-derived drug-loaded microparticles, the flexible regulator comprises a saponin compound and / or a steroid compound, and can regulate and control the hardness of the tumor cell-derived drug-loaded microparticles. The tumor cell-derived drug-loaded microparticles are modified, so that the enrichment and deep penetration of the drug-loaded microparticles in tumor tissues can be remarkably improved, and the efficient targeted delivery of the tumor tissues is realized. Meanwhile, efficient uptake of tumor stem cells to the medicine is promoted, targeted killing is achieved, the tumor stem cells are effectively removed, and tumor growth is remarkably inhibited. In addition, circulating tumor cells can be efficiently targeted, accurate delivery of tumor metastasis is achieved, and tumor metastasis is remarkably inhibited by inhibiting migration and invasion of tumor cells and reducing formation of lung metastasis.

The invention provides labdane diterpenoid compounds, a preparation method and application thereof, pharmaceutical compositions and application thereof, and relates to the technical field of extraction and separation. The labdane diterpenoid compound provided by the invention has pancreatic cancer stem cell inhibition activity and high anti-tumor activity, and has a good application prospect in preparation of drugs for treating pancreatic tumors and preventing and treating pancreatic cancer invasion and metastasis. Pharmacological activity experiments prove that the labdane type diterpenoid compound provided by the invention can inhibit pancreatic cancer PANC-1 cell proliferation, selectively inhibit self-renewal and dry characteristics of tumor stem cells and induce pancreatic cancer stem cell apoptosis, and has pancreatic cancer proliferation resisting activity; the compound can inhibit pancreatic cancer PANC-1 cell scratch fusion and cell migration, has the activity of inhibiting pancreatic cancer invasion and metastasis, and can be applied to preparation of drugs for preventing postoperative tumor recurrence and metastasis.

The invention relates to application of a bangia coumarin compound or a structural analogue of the bangia coumarin compound in preparation of an anti-brain cancer drug or reagent. The bangia coumarin compound is hesperel enol which is a bangia coumarin compound. And the structural analogue of the coumarin compound is a structural analogue hesperelactone hydrate of the coumarin compound hesperelactone of bangia fusco-purpurea. The compound can reduce the survival rate of brain cancer cells, reduce invasion of the brain cancer cells and inhibit the characteristics of brain cancer tumor stem cells, so that the compound can be used for preparing drugs or reagents for treating brain cancer. Meanwhile, the lowest concentration of the hesperidin hydrate for inhibiting the tumor stem cell characteristics of brain cancer is the same as that of a clinical medicine temozolomide, and the lowest concentration of the hesperenol is lower than that of the temozolomide. In addition, the anti-brain cancer effect of the nerolidinol further comprises the effect of inhibiting a brain cancer tumor stem cell marker.

The invention relates to the technical field of preparation of anti-cancer drugs, in particular to a temperature-sensitive hydrogel delivery drug based on an ALDH1 inhibitor and a preparation method and application of the temperature-sensitive hydrogel delivery drug. The thermo-sensitive hydrogel delivery drug is formed by compounding an ALDH1 inhibitor entrapment core, a tumor targeting modification layer and a thermo-sensitive hydrogel matrix system, and through triple technology integration, the defects that an existing delivery system is insufficient in targeting, uncontrollable in drug release and the like are overcome. The delivered drug can significantly inhibit the activity of tumor stem cells, reduce the toxicity of organs, and provide a new scheme for precise treatment of bladder cancer.

The invention discloses a bisindole compound as well as a synthesis method and anti-tumor application thereof. The molecular structure of the bisindole compound is shown in the specification. The bisindole compound XQ-010 has the remarkable effects that the bisindole compound XQ-010 can be used as an IL-6 / STAT3 signal channel regulator for tumor treatment, particularly has unique advantages in the aspect of inhibiting tumor growth and metastasis based on the inhibiting effect of the bisindole compound XQ-010 on CD133 + and CD44 + tumor stem cells, and has important clinical application value and development prospect.

The present invention discloses a microenvironment-responsive micelle, a preparation method thereof, and an application thereof in the preparation of a drug for inhibiting ovarian cancer recurrence, relating to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: dissolving polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, D-α-tocopheryl polyethylene glycol succinate, DSPE-PEG 2000 , DSPE-PEG 2000 -TK-PEG 5000 , paclitaxel, curcumol, and DSPE-PEG 2000 -FSHB in a solvent, transferring the solution to a rotary evaporation device, evaporating to remove the solvent to form a thin film; hydrating the thin film with a PBS solution, and then performing an extrusion treatment with a microporous membrane to obtain the microenvironment-responsive micelle. The microenvironment-responsive micelle can enhance the uptake of drugs by cancer stem cells, enabling the drugs to play a role in inhibiting tumor recurrence in vivo.

The invention discloses a reagent for inhibiting Acetyl-CoA or acetylase GCN5 and application of the reagent, and belongs to the technical field of biological medicine. A medicament comprising an agent capable of inhibiting the synthesis of Acetyl-CoA or capable of inhibiting GCN5; the tumor stem cells and the T cells interact, and the T cells can obtain a large amount of Acetyl-CoA from the tumor stem cells; according to the present invention, the Acetyl-CoA is adopted as the acetylation substrate, and under the action of the acetylase GCN5, the Blimp-1 can be acetylated, and the expression of the Blimp-1 can be down-regulated so as to inhibit the Trm cell differentiation; through targeted inhibition of synthesis of Acetyl-CoA and inhibition of GCN5, expression of Blimp-1 is up-regulated, Trm cell differentiation is maintained, and the anti-tumor ability of an organism is improved; the Acetyl-CoA and the GCN5 provided by the invention provide a new target spot for the treatment of the NSCLC (Non-Small Cells Leukemia).

This invention discloses a photothermal synergistic tumor stem cell inhibition system, its preparation method, and its applications. Addressing the current lack of effective treatments for large / unresectable GBM and its strongly immunosuppressive microenvironment, this invention constructs an injectable hydrogel platform (MIN-PPIC@iGel) integrating multiple key functions. This platform achieves a synergistic therapeutic model involving photothermal ablation for local tumor reduction, inhibition of residual GBM stem cells (GSCs), and activation of dendritic cells (DCs)-mediated anti-tumor immunity. Cellular experiments show that this invention can synergistically kill GL261 cells, significantly inhibit tumor stem cells and malignant phenotypes, induce significant ICD, and enhance DC maturation and activation effects. In a large-volume orthotopic GBM mouse model, a single intratumoral injection of MIN-PPIC@iGel combined with short-term near-infrared light irradiation doubled survival; further combination with antibody therapy unexpectedly achieved long-term tumor-free survival in 50% of mice, providing a new strategy for the local treatment of unresectable GBM.

The present invention relates to the use of a novel Arf1 inhibitor; a method for treating refractory, recurrent or metastatic cancer using these compounds; a method for selectively killing cancer stem cells and cancer cells by using the compounds and a specific dosing regimen; a method for targeting tumor stem cells to induce an anti-tumor immune response by inhibiting the Arf1 pathway, particularly the COPI / Arf1-lipolysis-β-oxidation pathway; a method for treating diseases associated with Arf1 pathway activity in mammals using the novel compounds; processes for preparing such compounds and their intermediates, and pharmaceutical compositions of related compounds.

The invention belongs to the technical field of biological medicines, and particularly relates to application of alpha-1, 2-high mannose type CD133 as a tumor stem cell sorting marker of intrahepatic cholangiocarcinoma. The lectin Cyanovirus-N (CVN) used in the invention is a 11kDa protein, is derived from Nostoc ellipsoporum, and has a specific recognition function on a terminal alpha-1, 2-Man part on high mannose (Man-8 or Man-9) glycan, the carbohydrate chain structure difference between intrahepatic cholangiocarcinoma tumor stem cells and tumor non-stem cells is studied, and the specific recognition function on the terminal alpha-1, 2-Man part on the non-stem cells of the intrahepatic cholangiocarcinoma tumor stem cells and the non-stem cells of the intrahepatic cholangiocarcinoma tumor non-stem cells is realized. The invention provides a novel marker alpha-1, 2-high mannose type CD133 protein for precise targeting of tumor stem cells of intrahepatic cholangiocarcinoma, and provides application of a novel precise marker for targeting treatment of tumor stem cells by recognizing sugar chain change through lectin.

The invention belongs to the technical field of biological medicine, and discloses application of mitoxantrone liposome (LipoMIT) in preparation of a medicine for inhibiting ovarian cancer stem cells and / or improving ovarian cancer relapse and / or drug resistance. It is found for the first time that LipoMIT has a good inhibiting effect on the ovarian cancer stem cells; the medicine can be used for improving the problems of relapse and drug resistance of ovarian cancer, not only can fill the blank of the problems of drug resistance and relapse in ovarian cancer treatment, but also can fill the technical blank of LipoMIT in the field of ovarian cancer treatment in the prior art. Lipo-MIT plays a role through targeting tumor stem cells, the risk of ovarian cancer recurrence and drug resistance is reduced fundamentally, the bottleneck that only tumor cells are killed but tumor stem cells cannot be eradicated in traditional treatment is broken through, and the clinical problems of high recurrence and high drug resistance of ovarian cancer in the prior art are solved.

The invention discloses application of a PKC beta inhibitor 1 as an NID1 inhibitor, and relates to the technical field of biological medicines. The invention provides an application of a PKC [beta] inhibitor 1 as an NID1 inhibitor in preparation of antitumor drugs. By constructing a systematic screening and verification system, it is determined for the first time that the PKC beta inhibitor 1 plays a significant anti-tumor activity by efficiently blocking the interaction between NID1 and integrin alpha5beta1, and an innovative treatment strategy is provided for targeting tumor stem cells and reversing drug resistance.

The invention relates to a hypoxia targeting hyaluronic acid nano delivery system and a construction method and application thereof, the construction method comprises the following preparation method: S1, dissolving 2-nitroimidazole and K2CO3 in dimethylformamide, carrying out high temperature alkali treatment, adding N-Boc-bromoethylamine, and carrying out high temperature reaction to obtain Boc-NIH; s2, dissolving the Boc-2-NIH in dichloromethane, adding trifluoroacetic acid for deprotection, and adjusting the pH value to be neutral, so as to obtain 2-NIH; s3, dissolving HA in deionized water, sequentially adding EDC and NHS to activate carboxyl, then adding 2-NIH, reacting at room temperature, and dialyzing to obtain a hypoxic targeting hyaluronic acid nano delivery carrier HA-NIH; s4, HA-NIH loads a drug, and the hypoxia targeted hyaluronic acid nano delivery system is formed. According to the invention, a bifunctional nano system with CD44 active targeting and hypoxia response release is successfully constructed, a dynamic regulation and control mechanism of HA molecular weight on a targeting-permeation-retention effect is provided, and a synergistic effect of tumor stem cell microenvironment specific response and drug space-time release is realized.

The application discloses a virus-mimic drug carrier targeting tumor stem cells and a preparation method and application thereof. The drug carrier can improve cell uptake efficiency by simulating physical surface characteristics of a biological system and can directly target tumor stem cells. In addition, the drug carrier can protect healthy tissues due to the targeting property, significantly reduce side effects of high-dose single use of a loaded drug such as PTC209, effectively enhance the response to tumor stem cells, inhibit tumor proliferation and metastasis, and reduce drug resistance of combined use of drugs such as cisplatin.

The application discloses a ROS / GSH responsive hyperbranched zwitterionic micelle and a preparation method and application thereof, and relates to a drug delivery system, ROS responsive zwitterionic micelles and GSH responsive zwitterionic micelles are prepared respectively, the ROS responsive zwitterionic micelles are loaded with anti-angiogenic drugs, and the GSH responsive zwitterionic micelles are loaded with anti-tumor stem cell drugs, so that the combined treatment of blood vessel normalization and tumor stem cell killing is realized, while the blood vessel normalization is realized, the restriction of the small intercellular gap of vascular endothelial cells caused by the blood vessel normalization on the enrichment and penetration of subsequent nano drugs in tumor sites is effectively solved, and the change of the interstitial pressure of tumor tissue caused by the blood vessel normalization is fully utilized to promote the deep penetration of small-size GSH responsive zwitterionic micelles into the internal region of the tumor, so that the killing of tumor stem cells is completed, and the combined treatment of the blood vessel normalization therapy and the tumor stem cell therapy is effectively realized.

The invention relates to the technical field of nano-drugs, in particular to a nano-drug for treating triple negative breast cancer as well as a preparation method and application of the nano-drug. The nano-drug takes hyaluronic acid modified hollow mesoporous copper zinc sulfide nanoparticles as a carrier, and cholesterol oxidase is loaded in the nano-drug. The preparation method adopts a one-pot wet chemical method, and a carrier with a regular structure is formed based on a Kirkendall effect. The nano-drug disclosed by the invention can be delivered to a tumor site in a targeted manner, is rapidly degraded in a weak acid microenvironment, synchronously releases cholesterol oxidase, metal ions with Fenton-like activity and H2S gas, and synergistically sensibilizes ferroptosis and efficiently eradicates tumor stem cells by triggering a cascade reaction of cholesterol depletion-lipid raft destruction-lipid peroxidation storm; a brand new treatment scheme is provided for solving the problems of drug resistance and relapse of the triple negative breast cancer.

The invention discloses an FGF2 inhibitor composition of a targeted iCAFs subgroup and application of the FGF2 inhibitor composition in bladder cancer prevention and treatment, and relates to the technical field of FGF2 inhibitor compositions of targeted iCAFs subgroups, the FGF2 inhibitor composition is used for preparing a medicine for bladder cancer prevention and treatment, the composition comprises an FGF2 inhibitor, and the FGF2 inhibitor can inhibit the bladder cancer by inhibiting interaction between FGF2 secreted by ICAM1 + iCAFs and tumor stem cell surface CD44, so that the bladder cancer can be prevented and treated, and the bladder cancer can be prevented and treated. According to the application disclosed by the invention, ICAM1 + inflammatory cancer related fibroblast iCAFs subpopulation in a bladder cancer recurrence related tumor microenvironment is targeted, a fibroblast growth factor FGF2 signal secreted by the ICAM1 + inflammatory cancer related fibroblast iCAFs subpopulation is specifically inhibited, the dependency support of the tumor microenvironment on the stemness maintenance of the tumor stem cells is destroyed, and the stemness maintenance of the recurrence related tumor stem cell subpopulation is inhibited. Therefore, the biological basis of tumor recurrence and progression is weakened from the source.

The invention provides an mRNA (messenger Ribonucleic Acid) medicine for inhibiting tumor stem cells and reducing the dryness of the tumor cells and a preparation method of the mRNA medicine. The mRNA medicine comprises any one or a combination of at least two of linear PTEN mRNA, self-replicating PTEN mRNA and annular PTEN mRNA; the linear PTEN mRNA comprises a 5 'UTR (Untranslated Region) sequence, a PTEN protein coding sequence and a 3' UTR sequence; the nucleotide sequence of the PTEN protein coding sequence comprises a sequence as shown in SEQ ID NO. 1. The mRNA nano-drug prepared by the invention not only has high transfection efficiency in tumor stem cells, but also can induce differentiation of the tumor stem cells and remarkably inhibit growth of the tumor stem cells; in drug-resistant tumor cells, the stemness of the drug-resistant tumor cells is inhibited, so that the sensitivity to chemotherapy, targeted antibodies, immunotherapy and the like is improved, and the killing effect of the drug is improved. The invention also shows an excellent anti-tumor effect in a human tumor cell line xenotransplantation model of the drug-resistant breast cancer in vivo, and provides a promising treatment strategy for the treatment of the drug-resistant breast cancer.

The present invention belongs to the technical field of biomedicine. Disclosed are a cannabicyclol derivative, a preparation method therefor and the use thereof. By using citral (3,7-dimethyl-2,6-octadienal) and a derivative thereof, and olivetol (1,3-dihydroxy-5-pentylbenzene) and a derivative thereof as starting materials, the cannabicyclol derivative is efficiently synthesized by means of a one-pot method under the combined action of ethylenediamine and a photocatalyst, thereby achieving simple and convenient operation, simplified steps and superior yield. In addition, the application potential of cannabicyclol and the derivative thereof in the research and development of tumor stem cell drugs is also explored, especially for glioblastoma stem cells, pancreatic cancer stem cells and liver cancer stem cells, showing the prospect of being an anti-tumor drug for specifically targeting tumor stem cells.

The utility model relates to the technical field of stem cell culture, and discloses a tumor stem cell three-dimensional culture device which comprises a container, a cover plate is arranged at the top of the container, a liquid adding pipe is fixedly connected to the end face of the cover plate in an inserted mode, the lower end of the liquid adding pipe fixedly communicates with a hollow plate, and a heating table is arranged in the hollow plate; the interior of the heating table is hollow, an electric heater is fixedly installed in the heating table, the container and the heating table are jointly provided with a circulation heating mechanism, the circulation heating mechanism and the heating table are both filled with heat conduction liquid, and a plurality of liquid inlet holes are formed in the bottom of the hollow plate. The temperature difference between the culture medium and the environment can be effectively reduced, and it is prevented that when the culture medium is added, the environment temperature becomes low, and culture of tumor stem cells is affected.

The application discloses a tumor stem cell inhibiting medicine based on gene regulation and a preparation method thereof, and belongs to the technical field of biological medicines. The medicine takes a targeted interference fragment of a tumor stem cell specific regulation gene TSC-G as a core active component, and is composed of only the targeted interference fragment and a modified liposome. The modified liposome is composed of DSPC, Chol and PEG-DSPE in a specific ratio, and has high targeting property and good stability. The preparation method comprises four steps of targeted interference fragment synthesis, modified liposome preparation, medicine assembly and purification, and has simple process and high purity. The medicine can effectively inhibit self-renewal, proliferation and differentiation of tumor stem cells, the tumor stem cell inhibition rate is greater than or equal to 88%, the tumor volume inhibition rate in vivo is greater than or equal to 78%, the medicine has no toxicity to normal body cells, the technical scheme is unique, the medicine can be used for clinical tumor treatment, and the problem of tumor recurrence and drug resistance can be solved from the root.

An apparatus for rapid screening of tumor stem cells and a method. The apparatus comprises a microscope slide (1) and a cover slip (2) for use under a microscope; the microscope slide (1) is located at the bottom and the cover slip (2) is located at the top; the microscope slide (1) and the cover slip (2) are sealed around their periphery and form an included angle of 2-10 degrees therebetween, the distance between front ends is 200-300 microns, the distance between rear ends is 100-150 microns, a liquid inlet tube (4) and a cleaning tube (5) are provided at the front ends, and a liquid outlet tube (6) is provided at the rear ends; the liquid inlet tube (4) is connected to a blood test vial (7), the cleaning tube (5) is connected to a cleaning vial or a reagent vial (8), and the liquid outlet tube (6) is connected to a blood collection vial (9); the microscope slide (1) is provided with one or more U-shaped grooves (11), the depth of the U-shaped groove (11) is 100-500 microns, and the width of the U-shaped groove (11) is 100-300 microns.